{"url_path":"/sec/med/8-k/2026-07-17/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-17","source_url":"https://www.sec.gov/Archives/edgar/data/910329/0001628280-26-048574-index.html","accession_number":"0001628280-26-048574","cik":"0000910329","ticker":"MED","issuer_name":"MEDIFAST INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/910329/0001628280-26-048574-index.html","primary_entity_key":"0000910329","primary_entity_name":"MEDIFAST INC"},"word_count":79,"has_tables":true,"body_markdown":"Item 9.01.    Financial Statements and Exhibits.\n\n(d)\n\nExhibits.\n\n99.1\n[Medifast Enters a New Era: Introducing Trilivy™, a Science-Backed Metabolic Health System](rebrandpressrelease.htm)\n\n104.1Cover Page Interactive Data File (embedded within the Inline XBRL Document)\n\nSignature\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nMEDIFAST, INC.\n\nBy:/s/ James P. Maloney\n\nJames P. Maloney\n\nChief Financial Officer\n\nDated: July 17, 2026"}